Breast Cancer Liquid Biopsy Market Report 2025 | Share and Forecast by 2033

The global breast cancer liquid biopsy market size reached USD 150.7 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 553.4 Million by 2033, exhibiting a growth rate

Global Breast Cancer Liquid Biopsy Market Statistics: USD 553.4 Million Value by 2033

Summary:

• The global breast cancer liquid biopsy market size reached USD 150.7 Million in 2024.

• The market is expected to reach USD 553.4 Million by 2033, exhibiting a growth rate (CAGR) of 14.77% during 2025-2033.

• North America leads the market, accounting for the largest breast cancer liquid biopsy market share.

• Reagent kits account for the majority of the market share in the product services segment due to their frequent use across various stages of the liquid biopsy process.

• Based on the circulating biomarkers, the market has been classified into circulating tumor cells (CTCs), cell-free DNA (cfDNA), extracellular vesicles (EVs), and others.

• On the basis of the end user, the market has been divided into reference laboratories, hospitals and physician laboratories, and others.

• The increasing preference for non-invasive diagnostic solutions is a primary driver of the breast cancer liquid biopsy market.

• Technological advancements in molecular biology and genetic sequencing, coupled with the rising trend of personalized medicine, are reshaping the breast cancer liquid biopsy market.

Industry Trends and Drivers:

• Rising demand for non-invasive diagnostic methods:

The growing patient and provider interest in non-surgical biopsy solutions in favor of traditional surgical biopsy is considered to be one of the primary driving forces behind the market growth. Liquid biopsy, such as protocols that allow blood sampling with minimal invasion through a scalpel, has become a favorite due to its less painful, faster, and safer approach. The benefits of this method in terms of easy application and shorter recovery time are driving clinics and hospitals to use such treatments. Also, it is easier to diagnose cancer at an early stage through circulating tumor DNA or ctDNA analysis which is perfect for increasing the productivity rate of patients. This growth is driven by the fact that healthcare facilities are always looking for ways to reduce the unpleasant discomfort of the patient as well as improve diagnosis accuracy.

• Technological advancements in biomarker detection:

Molecular diagnostic companies and research laboratories involved in development of breast cancer biomarkers are trying to invent better approaches to detect those markers in plasma. New technologies available in molecular biology, gene sequencing have led to identify cancer at the earlier stages, even prior to the development of symptoms – are making the crowd able to track a recurrence or response to the therapy in the long term. advancements such as the NGS, and digital PCR support the ability to increase the sensitivity and specificity of biomarker identification which therefore increases the diagnostic accuracy of the liquid biopsy The continuous improvement, expansion, and modernization of these technologies for better and accurate liquid biopsy is the driving force to their market growth.

• Growing focus on personalized medicine:

The growing emphasis on personalized medicine in oncology, with liquid biopsy playing a key role in its implementation, is fueling the market growth. Physicians are using genetic and molecular information collected from blood samples to customize treatment plans based on each patient's unique cancer profile. This approach is helping identify the most effective treatments for individuals, which is reducing adverse reactions and improving survival rates. In addition, liquid biopsy allows real-time monitoring of how cancer is responding to treatment, enabling more timely adjustments. As the shift towards precision medicine is growing, the integration of liquid biopsy into routine breast cancer care is providing a favorable market outlook.

Request for a sample copy of this report: https://www.imarcgroup.com/breast-cancer-liquid-biopsy-market/requestsample

Breast Cancer Liquid Biopsy Market Report Segmentation:

Breakup By Product Services:

• Reagent Kits

• Instruments

• Services

Reagent kits represent the largest segment as they provide the necessary tools and materials for detecting and analyzing cancer biomarkers.

Breakup By Circulating Biomarker:

• Circulating Tumor Cells (CTCs)

• Cell-Free DNA (cfDNA)

• Extracellular Vesicles (EVs)

• Others

Based on the circulating biomarkers, the market has been classified into circulating tumor cells (CTCs), cell-free DNA (cfDNA), extracellular vesicles (EVs), and others.

Breakup By End User:

Breast Cancer Liquid Biopsy Market Segments by End User

• Reference Laboratories

• Hospitals and Physician Laboratories

• Others

On the basis of the end user, the market has been divided into reference laboratories, hospitals and physician laboratories, and others.

Breakup By Region:

• North America (United States, Canada)

• Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)

• Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)

• Latin America (Brazil, Mexico, Others)

• Middle East and Africa

North America enjoys the leading position in the breast cancer liquid biopsy market due to its advanced healthcare infrastructure, high adoption of cutting-edge technologies, and increasing investments in research and development (R&D) activities for cancer.

Top Breast Cancer Liquid Biopsy Market Leaders: The breast cancer liquid biopsy market research report outlines a detailed analysis of the competitive landscape, offering in-depth profiles of major companies. Some of the key players in the market are:

Breast Cancer Liquid Biopsy Market Key Players

• Biocept Inc.

• Bio-Rad Laboratories Inc.

• F. Hoffmann-La Roche AG

• Fluxion Biosciences Inc.

• Guardant Health Inc.

• Illumina Inc.

• Menarini Silicon Biosystems (The Menarini Group)

• NeoGenomics Laboratories Inc.

• Qiagen and Sysmex Europe SE (Sysmex Corporation).

Note: If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us:

IMARC Group is a global management consulting firm that helps the world's most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us:

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: [e-mail]

Tel No:(D) [phone]

United States: [phone]